Hydrix Limited launches first heart alerting technology in Australia

Hydrix Limited, popular company within the Information Technology sector has announced to launch a heart attack alerting machine in Australia. It is the first technology of its kind.

According to reports, Hydrix has obtained exclusive rights for sale of AngelMed Guardian System (Guardian) in Australia in addition to distribution rights in significant Asian countries including Japan and Singapore.

World’s first FDA approved technology, Guardian is a monitoring device which alerts patients about an impending Acute Coronary Syndrome (ACS), including unstable angina and heart attacks.  Experts observe, the faster a heart attack is diagnosed, greater are the chances of full recovery among patients. The implanted Guardian device helps in recognizing ACS symptoms with enhanced accuracy and alerts the patient to immediately seek help. The device thus eliminates the uncertainty of self-diagnosis.

Guardian is especially designed for patients who have previously suffered an ACS event and hence remain at a higher risk of a recurring event. Guardian monitors the patient’s heart signal 24/7 with the help of Artificial Intelligence in order to identify an impending heart attack.

When the implanted device suspects a heart activity, the device vibrates within the chest, this alerts the patients to seek immediate help through a separate wireless pager-like device which notifies through flashing LEDs and sound.

For the AngelMed’s US clinical trials, the device was tested on 900 patients approximately and the results concluded improved patient quality life, lower morbidity rates, relatively minimum heart damage and reduced length of hospital stay. This further also led to minimal healthcare costs.

With regards to the latest launch, Hydrix Chairman, Gavin Coote said, “Coronary heart disease is the leading cause of death globally. The AngelMed Guardian will help save lives and lower overall healthcare costs. We are pleased and proud to be able to collaborate with AngelMed founder and CEO Dr. David Fischell. He and his family were early developers of pacemaker and coronary stent technologies which later went on to become ‘gold standards’ in cardiac care, and we equally expect the Guardian to become a game changer.”